Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Shota Fukuoka
Observed name:
S. Fukuoka
Institutions:
The Cancer Institute Hospital,
Japanese Foundation For Cancer Research
Observed institutions:
The Cancer Institute Hospital,
National Cancer Center Hospital East,
Japanese Foundation For Cancer Research
ORCID:
0000-0001-9460-4486
Observed ORCID:
0000-0001-9460-4486
OpenAlex ID:
A5112057394
500TiP An open label phase Ib/II study of trastuzumab deruxtecan (T-DXd) in combination with nivolumab and CAPOX for patients with HER2-low expressing gastroesophageal adenocarcinoma (EPOC2203)
2024
·
Y. Aoki
, I. Nakayama
, et al.
·
Annals of Oncology
·
5
PDF
An open-label phase Ib/II study of trastuzumab deruxtecan combined with nivolumab and CAPOX for HER2-low gastroesophageal adenocarcinoma
2025
·
Y. Aoki
, I. Nakayama
, et al.
·
ESMO Gastrointestinal Oncology
·
4
Impact of early tumor shrinkage on survival outcomes in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan in third- or later-line settings
2025
·
Koshiro Fukuda
, Hiroki Osumi
, et al.
·
Therapeutic Advances in Gastroenterology
·
4
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab deruxtecan efficacy in patients with HER2-positive gastric cancer
2026
·
Koichiro Yoshino
, Manabu Takamatsu
, et al.
·
Gastric Cancer
·
3
PDF
Clinicopathological characteristics and survival in metastatic colorectal cancer with short-form APC mutations.
2024
·
Hiroki Osumi
, Akira Ooki
, et al.
·
Journal of Clinical Oncology
·
3
PDF
A multicentre phase I/II study of TAS-102 with nintedanib in patients with metastatic colorectal cancer refractory to standard therapies (N-TASK FORCE: EPOC1410); Phase I results
2016
·
T. Nishina
, Y. Kuboki
, et al.
·
Annals of Oncology
·
3
Patient characteristics related to screening failure in Phase I trials
2025
·
Haruka Ozaki
, Eriko Miyawaki
, et al.
·
BMC Cancer
·
2
Phase II study of neoadjuvant chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel for resectable esophageal squamous cell carcinoma.
2025
·
Shun Yamamoto
, Satoru Matsuda
, et al.
·
Journal of Clinical Oncology
·
2
Advantages of adjuvant chemotherapy using S-1 following minimally invasive gastrectomy for gastric cancer versus open surgery: a propensity score-matched analysis
2024
·
Motonari Ri
, Naoki Nishie
, et al.
·
Gastric Cancer
·
2
PDF
An open-label phase Ib/II study of trastuzumab deruxtecan combined with nivolumab and CAPOX in patients with HER2-low gastroesophageal adenocarcinoma (EPOC2203).
2026
·
Yu Aoki
, Izuma Nakayama
, et al.
·
Journal of Clinical Oncology
·
1
Predictive factors for early mortality after regorafenib or trifluridine/tipiracil initiation in metastatic colorectal cancer
2026
·
Toshiki Masuishi
, Shota Fukuoka
, et al.
·
The Oncologist
·
1
Semiquantitative CLDN18 expression and clinical outcomes in patients with CLDN18-positive gastric cancer treated with zolbetuximab plus chemotherapy
2026
·
A. Ooki
, K. Nakano
, et al.
·
ESMO Gastrointestinal Oncology
·
1
PDF
Early Higher Plasma Regorafenib Concentration Predicts Shorter PFS in Japanese Patients With mCRC
2025
·
Kazuo Kobayashi
, Takeru Wakatsuki
, et al.
·
Clinical and Translational Science
·
1
PDF
Association of early tumor shrinkage with survival in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan.
2025
·
Koshiro Fukuda
, Akira Ooki
, et al.
·
Journal of Clinical Oncology
·
1
PDF
Evaluation of clinical outcomes and prognostic factors in patients with metastatic appendiceal adenocarcinoma treated with first-line chemotherapy: A multi-institutional retrospective study
2026
·
Koshiro Fukuda
, Hiroki Osumi
, et al.
·
Therapeutic Advances in Medical Oncology
Clinical benefits of early-phase clinical trials for rare malignancies: Asian single-center analysis.
2026
·
Akihiro Ohmoto
, Takahiro Kogawa
, et al.
·
Journal of Clinical Oncology
A multicenter single-arm phase II trial evaluating the safety and efficacy of panitumumab and irinotecan in patients with Neo RAS wild-type metastatic colorectal cancer (C-PROWESS trial).
2026
·
Hiroki Osumi
, Tadamichi Denda
, et al.
·
Journal of Clinical Oncology
PDF
Prognostic value of perioperative ctDNA monitoring in patients with esophageal squamous cell carcinoma (ESCC) undergoing neoadjuvant chemotherapy (NAC) and surgery.
2026
·
Akinori Watanabe
, Satoru Matsuda
, et al.
·
Journal of Clinical Oncology
Increased treatment options and improved survival in real-world patients with HER2-positive advanced gastric cancer from 2011 to 2023
2026
·
Keitaro Shimozaki
, Akira Ooki
, et al.
·
Therapeutic Advances in Gastroenterology
C-reactive Protein to Albumin Ratio as a Prognostic Biomarker in Patients with Esophageal Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitor- based Therapy
2026
·
Koichiro Yoshino
, Akihiko Okamura
, et al.
·
Research Square
PDF
Prognostic value of KRAS exon 3, exon 4, and NRAS mutations in pathological stage III colon cancer.
2026
·
Kaoru Yoshikawa
, Hiroki Osumi
, et al.
·
Journal of Clinical Oncology
PDF
Clinical significance of serum tumor marker dynamics during preoperative chemotherapy and hepatectomy for colorectal liver metastases.
2026
·
Shohei Udagawa
, Hiroki Osumi
, et al.
·
Journal of Clinical Oncology
PDF
Phase II study of neoadjuvant chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel for resectable esophageal squamous cell carcinoma: Survival analysis.
2026
·
Satoru Matsuda
, Shun Yamamoto
, et al.
·
Journal of Clinical Oncology
PDF
Effect of initial corticosteroid doses and second-line immunosuppressants on overall duration of corticosteroid therapy for immune-related adverse events in gastrointestinal tumors.
2026
·
Emiko Tange
, Koichi Takeda
, et al.
·
Journal of Clinical Oncology
PDF
Managing dual primary liver metastases from breast and colorectal cancers
2025
·
Ryota Ito
, Atsushi Oba
, et al.
·
Clinical Journal of Gastroenterology
Show more works
View as search
Works count:
33
Citation count:
33
H-index:
3
I10-index:
Year
Topic
Type